Genetic Polymorphism of Human CYP2E1: Characterization of Two Variant Alleles

xPharm- The Comprehensive Pharmacology Reference

QUICK SEARCH:

[advanced]

	Author:		Keyword(s):
Year:		Vol:		Page:

This Article

	Full Text
	Full Text (PDF)
	Submit a response
	Alert me when this article is cited
	Alert me when eLetters are posted
	Alert me if a correction is posted

Services

	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via Google Scholar

Google Scholar

	Articles by Hu, Y.
	Articles by Ingelman-Sundberg, M.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Hu, Y.
	Articles by Ingelman-Sundberg, M.

This article has been cited by other articles:

Amal Al Omari and D. J. Murry
Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance
Journal of Pharmacy Practice, June 1, 2007; 20(3): 206 - 218.
[Abstract] [PDF]

J. Meletiadis, S. Chanock, and T. J. Walsh
Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy
Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787.
[Abstract] [Full Text] [PDF]

J.-Y. Park, K.-A. Kim, P.-W. Park, and J.-M. Ha
Effect of High-Dose Aspirin on CYP2E1 Activity in Healthy Subjects Measured Using Chlorzoxazone as a Probe
J. Clin. Pharmacol., January 1, 2006; 46(1): 109 - 114.
[Abstract] [Full Text] [PDF]

Y. Guo, Y. Zhang, Y. Wang, X. Chen, D. Si, D. Zhong, J. P. Fawcett, and H. Zhou
ROLE OF CYP2C9 AND ITS VARIANTS (CYP2C9*3 AND CYP2C9*13) IN THE METABOLISM OF LORNOXICAM IN HUMANS
Drug Metab. Dispos., June 1, 2005; 33(6): 749 - 753.
[Abstract] [Full Text] [PDF]

J. E. Aldridge, J. A. Gibbons, M. M. Flaherty, M. L. Kreider, J. A. Romano, and E. D. Levin
Heterogeneity of Toxicant Response: Sources of Human Variability
Toxicol. Sci., November 1, 2003; 76(1): 3 - 20.
[Abstract] [Full Text] [PDF]

T. A. Glauser
Advancing the Medical Management of Epilepsy: Disease Modification and Pharmacogenetics
J Child Neurol, January 1, 2002; 17(1_suppl): S85 - S93.
[Abstract] [PDF]

D. G. McCarver
ADH2 and CYP2E1 Genetic Polymorphisms: Risk Factors for Alcohol-Related Birth Defects
Drug Metab. Dispos., April 1, 2001; 29(4): 562 - 565.
[Abstract] [Full Text]

M. Ingelman-Sundberg
Implications of Polymorphic Cytochrome P450-Dependent Drug Metabolism for Drug Development
Drug Metab. Dispos., April 1, 2001; 29(4): 570 - 573.
[Abstract] [Full Text]

S. M. Lankford, S. A. Bai, and J. A. Goldstein
Cloning of Canine Cytochrome P450 2E1 cDNA: Identification and Characterization of Two Variant Alleles
Drug Metab. Dispos., August 1, 2000; 28(8): 981 - 986.
[Abstract] [Full Text]

W. Tan, N. Song, G.-Q. Wang, Q. Liu, H.-J. Tang, F. F. Kadlubar, and D.-X. Lin
Impact of Genetic Polymorphisms in Cytochrome P450 2E1 and Glutathione S-Transferases M1, T1, and P1 on Susceptibility to Esophageal Cancer among High-Risk Individuals in China
Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 551 - 556.
[Abstract] [Full Text]

T. E. Jackson, P. D. Lilly, L. Recio, P. M. Schlosser, and M. A. Medinsky
Inhibition of Cytochrome P450 2E1 Decreases, but Does Not Eliminate, Genotoxicity Mediated by 1,3-Butadiene
Toxicol. Sci., June 1, 2000; 55(2): 266 - 273.
[Abstract] [Full Text] [PDF]

				J. Meletiadis, S. Chanock, and T. J. Walsh Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787. [Abstract] [Full Text] [PDF]

				J.-Y. Park, K.-A. Kim, P.-W. Park, and J.-M. Ha Effect of High-Dose Aspirin on CYP2E1 Activity in Healthy Subjects Measured Using Chlorzoxazone as a Probe J. Clin. Pharmacol., January 1, 2006; 46(1): 109 - 114. [Abstract] [Full Text] [PDF]

				Y. Guo, Y. Zhang, Y. Wang, X. Chen, D. Si, D. Zhong, J. P. Fawcett, and H. Zhou *ROLE OF CYP2C9 AND ITS VARIANTS (CYP2C93 AND CYP2C913) IN THE METABOLISM OF LORNOXICAM IN HUMANS* Drug Metab. Dispos., June 1, 2005; 33(6): 749 - 753. [Abstract] [Full Text] [PDF]

				J. E. Aldridge, J. A. Gibbons, M. M. Flaherty, M. L. Kreider, J. A. Romano, and E. D. Levin Heterogeneity of Toxicant Response: Sources of Human Variability Toxicol. Sci., November 1, 2003; 76(1): 3 - 20. [Abstract] [Full Text] [PDF]

				T. A. Glauser Advancing the Medical Management of Epilepsy: Disease Modification and Pharmacogenetics J Child Neurol, January 1, 2002; 17(1_suppl): S85 - S93. [Abstract] [PDF]

				D. G. McCarver ADH2 and CYP2E1 Genetic Polymorphisms: Risk Factors for Alcohol-Related Birth Defects Drug Metab. Dispos., April 1, 2001; 29(4): 562 - 565. [Abstract] [Full Text]

				M. Ingelman-Sundberg Implications of Polymorphic Cytochrome P450-Dependent Drug Metabolism for Drug Development Drug Metab. Dispos., April 1, 2001; 29(4): 570 - 573. [Abstract] [Full Text]

				S. M. Lankford, S. A. Bai, and J. A. Goldstein Cloning of Canine Cytochrome P450 2E1 cDNA: Identification and Characterization of Two Variant Alleles Drug Metab. Dispos., August 1, 2000; 28(8): 981 - 986. [Abstract] [Full Text]

				W. Tan, N. Song, G.-Q. Wang, Q. Liu, H.-J. Tang, F. F. Kadlubar, and D.-X. Lin Impact of Genetic Polymorphisms in Cytochrome P450 2E1 and Glutathione S-Transferases M1, T1, and P1 on Susceptibility to Esophageal Cancer among High-Risk Individuals in China Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 551 - 556. [Abstract] [Full Text]

				T. E. Jackson, P. D. Lilly, L. Recio, P. M. Schlosser, and M. A. Medinsky Inhibition of Cytochrome P450 2E1 Decreases, but Does Not Eliminate, Genotoxicity Mediated by 1,3-Butadiene Toxicol. Sci., June 1, 2000; 55(2): 266 - 273. [Abstract] [Full Text] [PDF]